Valiant Labs Q1FY27: consolidated PAT surges ~11x YoY to Rs 21.1 Cr as margins triple

Valiant Laboratories' consolidated (primary) Q1 FY27 print shows revenue of Rs 115.29 Cr, up 146.2% YoY from Rs 46.82 Cr and 25.3% QoQ from Rs 91.98 Cr, with PAT of Rs 21.10 Cr versus Rs 1.82 Cr a year ago (~11.6x) and Rs 1.76 Cr last quarter. EPS rose to Rs 3.89 from Rs 0.42 YoY. There is no prior guidance or concall commentary on record for this company, and no management press release was available in the source set to cross-check against the numbers, so both angles are unaddressed by the company itself here; with WebSearch unavailable this run, street/consensus expectations could not be verified either, so vsStreet is marked unknown rather than assumed.

The entire margin story sits on the operating line: consolidated NPM expanded to 18.3% from 3.84% YoY (and from 1.91% QoQ), while EBITDA margin (OPM) rose to roughly 25.4% from 5.12% YoY and 5.23% QoQ. No exceptional items are reported in any period, so this is a straight operating re-rating, not a one-off gain. Standalone (parent-only) results are far more modest by comparison −revenue of Rs 73.42 Cr (+43.9% YoY) and PAT of Rs 9.48 Cr (+422% YoY, still off a small base) −a divergence of well over 3% from the consolidated growth rate. The gap traces to the single consolidated subsidiary, Valiant Advanced Sciences Private Limited: per the auditor's Other Matters note, that subsidiary alone reported total income of Rs 115.29 Cr and PAT of Rs 21.10 Cr for the quarter, numbers that match the group's consolidated totals almost exactly, meaning the subsidiary −not the listed parent's own chemicals operations −is now the dominant driver of group scale and profitability.

For context: this is the second-highest quarterly PAT of the last 6 quarters; PAT has now risen for 2 consecutive quarters; revenue is at a 6-quarter high.

This consolidation structure sits alongside two pending corporate developments from the context: Valiant Organics' announced move (May 20, 2026) to acquire a 34.26% stake in Valiant Labs, and the company's own flag (May 16, 2026) that it is evaluating restructuring options −neither has disclosed financial terms yet, and neither is reflected in this quarter's P&L. A separate Rs 18 lakh GST penalty (May 30, 2026, with some charges dropped) is immaterial against Rs 21.10 Cr of quarterly PAT and doesn't move the numbers.